BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2019 2:14:06 AM | Browse: 37 | Download: 50
Publication Name World Journal of Gastroenterology
Manuscript ID 50618
Country of Manuscript Source China
Received
2019-07-30 08:52
Peer-Review Started
2019-07-30 08:52
To Make the First Decision
2019-08-19 00:33
Return for Revision
2019-08-23 09:58
Revised
2019-09-05 13:14
Second Decision
2019-09-06 12:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-09-09 05:56
Articles in Press
2019-09-09 05:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
2019-09-19 02:44
Typeset the Manuscript
2019-09-27 11:14
Publish the Manuscript Online
2019-09-30 02:14
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Basic Study
Article Title Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Li Wei, Jing-Yun Wen, Jie Chen, Xiao-Kun Ma, Dong-Hao Wu, Zhan-Hong Chen and Jiang-Long Huang
ORCID
Author(s) ORCID Number
Li Wei http://orcid.org/0000-0003-2999-0979
Jing-Yun Wen http://orcid.org/0000-0001-5560-7115
Jie Chen http://orcid.org/0000-0002-7503-8236
Xiao-Kun Ma http://orcid.org/0000-0002-6793-0232
Dong-Hao Wu http://orcid.org/0000-0002-8340-2253
Zhan-Hong Chen http://orcid.org/0000-0003-3192-9026
Jiang-Long Huang http://orcid.org/0000-0002-3784-8465
Funding Agency and Grant Number
Correspondence To Jiang-Long Huang, MD, Associate Professor, Chief Doctor, Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, No.600 Tianhe Rd, Guangzhou 510630, Guangdong Province, China. leichende21743@163.com
Keywords ADAM28; Drug resistance; Overexpression; Poor prognosis; Drug metabolism; Gemcitabine
Core Tip This study demonstrated that ADAM28 was overexpressed in pancreatic cancer, and the ADAM28 level was elevated in the gemcitabine-resistant pancreatic cancer cells. Furthermore, ADAM28 overexpression could predict the poor prognosis in pancreatic cancer. Also, overexpression of ADAM28 could attenuate the cell viability inhibition by gemcitabine. Similarly, knockdown of ADAM28 could enhance the cell viability inhibition by gemcitabine. Interestingly, ADAM28 was identified as a mediator, which was closely involved in the regulation of the drug resistance signaling pathway. ADAM28 was identified as a novel therapeutic target for pancreatic cancer, especially in the drug resistance of gemcitabine.
Publish Date 2019-09-30 02:14
Citation Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603
Url https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i37.5590
Full Article (PDF) WJG-25-5590.pdf
Full Article (Word) WJG-25-5590.docx
Manuscript File 50618-Review_Edited.doc
Answering Reviewers 50618-Answering reviewers.pdf
Audio Core Tip 50618-Audio core tip.mp3
Biostatistics Review Certificate 50618-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 50618-Conflict-of-interest statement.pdf
Copyright License Agreement 50618-Copyright license agreement.pdf
Institutional Review Board Approval Form or Document 50618-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 50618-Language certificate.pdf
Peer-review Report 50618-Peer-review(s).pdf
Scientific Misconduct Check 50618-Scientific misconduct check.pdf
Scientific Editor Work List 50618-Scientific editor work list.pdf